Reading TNYA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TNYA free→Reading TNYA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TNYA free→QuarterlyIQ Insights · TNYA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Tenaya Therapeutics, Inc. (the “Company”) amended and restated its 2021 Equity Incentive Plan (the “A&R 2021 Equity Incentive Plan”), effective as of May 27, 2026 upon approval by the stockholders of the Company at the Annual Meeting (as defined below). The amendments to the A&R 2021 Equity Incentive Plan included (1) a one-time increase to the num…
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Results of Operations and Financial Condition. On March 11, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2025 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information furnished in this
Entry into a Material Definitive Agreement. Collaboration Agreement On March 4, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with Alnylam Pharmaceuticals, Inc. (“Alnylam”), pursuant to which the parties agreed to a research collaboration to discover and validate novel gene targets for the potential treatment of cardiovascular disease. The Company and Alnylam will nominate an aggregate of 15 targets, align on which targe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective January 26, 2026, the Board of Directors (the “Board”) of the Company approved an amendment and restatement to the Tenaya Therapeutics, Inc. 2024 Inducement Equity Incentive Plan (as amended, the “Inducement Plan”) to increase the number of shares reserved for issuance under the Inducement Plan. Subject to the adjustment provisions of the…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 28, 2026, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between December 12, 2025, through January 27, 2026, the Company did not meet the minimu…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Resignation of Director On December 31, 2025, in connection with his retirement, David Goeddel submitted his resignation from the board of directors (the “Board”) of Tenaya Therapeutics, Inc. (the “Company”) and as a member of all committees of the Board, effective January 26, 2026. Dr. Goeddel’s resignation was voluntary and did not result fro…
Entry into a Material Definitive Agreement. On December 11, 2025, Tenaya Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the underwriters listed therein (the “Underwriters”), relating to the issuance and sale in a firm commitment underwritten public offering (the “Offering”) of 50,000,000 units (the “Units”), at a public offering price of $1…
Results of Operations and Financial Condition. On November 10, 2025, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this
Results of Operations and Financial Condition. On August 6, 2025, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 15, 2025, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between March 3, 2025, through April 12, 2025, the Company did not meet the minimum bid pr…
Costs Associated with Exit or Disposal Activities. On March 27, 2025, Tenaya Therapeutics, Inc. (“Tenaya”) approved the implementation of a restructuring plan (the “Restructuring Plan”) to further focus company resources on generating data from MyPEAK TM -1, evaluating TN-201 as a gene therapy treatment for Myosin Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy, and RIDGE TM -1, evaluating TN-401 as a gene therapy treatment for plakophilin-2 (PKP2)-associated arrhythmogenic…
Results of Operations and Financial Condition. On March 10, 2025, Tenaya Therapeutics, Inc. (“Tenaya or the “Company”) issued a press release announcing Tenaya’s financial results for the quarter and the year ended December 31, 2024 (“the Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this
Entry into a Material Definitive Agreement. On March 3, 2025, Tenaya Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the underwriters listed therein (the “Underwriters”), relating to the issuance and sale in a firm commitment underwritten public offering (the “Offering”) of 75,000,000 units (the “Units”), at a public offering price of $0.70…
Other Information. Effective March 3, 2025, the Company suspended and terminated the prospectus (the “ATM Prospectus”) related to the Common Stock issuable pursuant to the terms of a sales agreement, dated August 10, 2022, by and between the Company and Leerink Partners LLC (the “Sales Agreement”). As a result, the Company will not make any sales of the Company’s securities pursuant to the Sales Agreement unless and until a new prospectus, prospectus supplement or a new registration statement…
by reference. (e) Repricing of Designated Underwater Options The Board of Directors (the “Board”) of the Company approved an option repricing applicable to Faraz Ali, the Company’s Chief Executive Officer, effective as of February 6, 2025 (the “Effective Date”), which mirrored the terms of a repricing approved on January 24, 2025 applicable to certain other service providers as described on the Form 8-K filed by the Company on January 28, 2025 (the “Employee Repricing”), except that for Mr. A…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. ( e) Repricing of Designated Underwater Option s The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Tenaya Therapeutics, Inc. (the “Company”) approved an option repricing, effective as of January 24, 2025 (the “Effective Date”). The repricing generally applied to nonstatutory stock options to purcha…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.